Bicycle Therapeutics PLC
BCYC7.160USD
+0.240+3.47%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
495.86MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Bicycle Therapeutics PLC Unternehmen
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Unternehmensinformationen
BörsenkürzelBCYC
Name des UnternehmensBicycle Therapeutics PLC
IPO-datumMay 23, 2019
CEODr. Kevin Lee, Ph.D.
Anzahl der mitarbeiter305
WertpapierartDepository Receipt
GeschäftsjahresendeMay 23
AddresseBlocks A & B, Portway Building
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited Kingdom
PostleitzahlCB21 6GS
Telefon11441223261503
Websitehttps://www.bicycletherapeutics.com/
BörsenkürzelBCYC
IPO-datumMay 23, 2019
CEODr. Kevin Lee, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
--
--
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Sands
Mr. Stephen Sands
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Charles Swanton
Charles Swanton
Independent Director
Independent Director
--
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
21.83%
Forbion Capital Partners
6.92%
Armistice Capital LLC
5.61%
Westfield Capital Management Company, L.P.
5.58%
Invus Public Equities Advisors, LLC
4.04%
Andere
56.02%
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
21.83%
Forbion Capital Partners
6.92%
Armistice Capital LLC
5.61%
Westfield Capital Management Company, L.P.
5.58%
Invus Public Equities Advisors, LLC
4.04%
Andere
56.02%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
46.70%
Investment Advisor
16.54%
Investment Advisor/Hedge Fund
13.13%
Venture Capital
7.06%
Research Firm
4.64%
Individual Investor
1.60%
Pension Fund
0.24%
Family Office
0.05%
Andere
10.05%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
261
46.21M
95.43%
-15.11M
2025Q1
263
46.04M
96.46%
-15.64M
2024Q4
263
44.84M
86.26%
-16.34M
2024Q3
260
44.49M
67.19%
-14.65M
2024Q2
252
44.12M
95.17%
-7.15M
2024Q1
268
34.84M
83.52%
-13.88M
2023Q4
272
34.95M
93.64%
-12.28M
2023Q3
272
41.70M
105.20%
-747.70K
2023Q2
255
34.13M
112.16%
-8.01M
2023Q1
245
32.53M
108.64%
-4.04M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baker Bros. Advisors LP
10.89M
22.79%
-8.80K
-0.08%
Mar 31, 2025
Forbion Capital Partners
3.45M
7.23%
--
--
Mar 31, 2025
Armistice Capital LLC
2.67M
5.59%
+476.00K
+21.68%
Mar 31, 2025
Westfield Capital Management Company, L.P.
2.66M
5.56%
+46.97K
+1.80%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.81M
3.8%
-26.65K
-1.45%
Mar 31, 2025
Point72 Asset Management, L.P.
3.69M
7.73%
-862.83K
-18.94%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.54M
3.22%
-48.54K
-3.06%
Mar 31, 2025
Candriam Luxembourg S.A.
1.21M
2.53%
-20.80K
-1.69%
May 31, 2025
Long Focus Capital Management LLC
1.29M
2.71%
+750.66K
+138.22%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
